TAPI-0

TAPI-0 is a TACE (TNF-α converting enzyme; ADAM17) inhibitor with an IC50 of 100 nM. TAPI-0 is a MMP inhibitor and also attenuates TNF-α processing[1][2].

Product Specifications

CAS Number

[163958-73-4]

UNSPSC

12352209

Hazard Statement

H301

Target

Bacterial; MMP; TNF Receptor

Type

Reference compound

Related Pathways

Anti-infection; Apoptosis; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/tapi-0.html

Purity

98.98

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

ONC(C[C@H](C(N[C@H](C(N[C@H](C(N)=O)C)=O)CC1=CC2=C(C=C1)C=CC=C2)=O)CC(C)C)=O

Molecular Formula

C24H32N4O5

Molecular Weight

456.53

Precautions

H301

References & Citations

[1]Amit Balakrishnan, et al. Metalloprotease inhibitors GM6001 and TAPI-0 inhibit the obligate intracellular human pathogen Chlamydia trachomatis by targeting peptide deformylase of the bacterium. J Biol Chem. 2006 Jun 16;281 (24) :16691-9.|[2]Shiori Haga, et al. TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds. Antiviral Res. 2010 Mar;85 (3) :551-5.